Core Insights - The company reported a revenue of 242.09 million, representing a year-on-year growth of 14.93% [1] - The net profit attributable to shareholders reached 60.79 million, showing a year-on-year increase of 4.74% [1] - Significant growth was observed in the two core business segments, with the raw materials segment sales increasing by 13.94% and the intermediates segment sales surging by 29.24% [1] - The overall gross margin improved by 3.56 percentage points due to capacity optimization and the release of scale effects, indicating enhanced profitability [1] - The company's overall operations remain stable and show a positive trend [1]

Core Viewpoint - The company has achieved significant breakthroughs in its international expansion, with overseas sales revenue increasing by 53.04% year-on-year, accounting for 55.61% of total revenue [1] Group 1: International Market Performance - The company's products are now available in nearly 100 countries and regions across Europe, North America, South America, Asia, Africa, and Oceania [1] - The participation in international CPHI exhibitions and the advancement of product registration and qualified supplier listings have contributed to the gradual increase in market penetration in high-end markets such as Europe and the United States [1] Group 2: Global Operations - The company's global operational capabilities are continuously improving, reflecting its commitment to expanding its presence in international markets [1]

Core Viewpoint - The company, Haisen Pharmaceutical, is significantly increasing its investment in research and development, indicating a strong commitment to technological innovation and sustainable growth in its product pipeline [1] Group 1: Financial Performance - In the first half of 2025, the company's R&D investment reached 17.71 million yuan, representing a year-on-year increase of 52.83% [1] - R&D expenses accounted for 7.32% of the company's operating revenue, highlighting the emphasis on innovation [1] Group 2: Product Development - The company currently has 17 ongoing research projects across various therapeutic areas, including antiviral, antidepressant, lipid-lowering, non-steroidal anti-inflammatory, anti-rheumatic, and anti-ulcer treatments [1] - The establishment of a new pilot workshop and strengthened collaboration with research institutions are part of the strategy to accelerate the transformation of R&D results [1]

Financial Performance - The company achieved a revenue of 242.09 million yuan in the first half of 2025, representing a year-on-year growth of 14.93% [2] - Net profit attributable to shareholders was 60.79 million yuan, with a year-on-year increase of 4.74% [2] - The gross profit margin improved by 3.56 percentage points compared to the same period last year, reaching 29.24% [2][4] International Market Expansion - Overseas sales increased by 53.04%, contributing to 55.61% of total revenue [3][6] - The company has participated in international exhibitions for over 20 years, expanding its presence in markets such as Europe, India, and Brazil, and plans to enter more countries [3] - The company aims to strengthen its position in existing markets like India, Mexico, and Brazil while increasing investments in the US and Europe [3] Sales and Market Strategy - The sales of raw materials and intermediates grew by 13.94% and 29.24% respectively, driving overall performance [5][12] - The company has optimized its production capacity to ensure stable supply and has adjusted sales strategies to meet market demand [5][11] - The company is focused on maintaining long-term relationships with strategic partners, enhancing management levels, and expanding its customer base [9][14] Research and Development - R&D expenses amounted to 17.71 million yuan, accounting for 7.32% of revenue, with a year-on-year increase of 52.83% [10] - The company has 17 ongoing R&D projects, including products for antiviral and anti-inflammatory treatments [10] - A new pilot workshop is being established to facilitate the industrialization of R&D outcomes [10] Asset Growth and Investment - Total assets increased by 2.61% compared to the beginning of the period, while net assets attributable to shareholders grew by 4.03% [5] - The company is advancing the construction of a new green and intelligent pharmaceutical production base to enhance production capacity [5][11] Cost Management - Total operating costs were 172.70 million yuan, up 18.86% year-on-year, with management expenses rising by 29.34% [8] - The company emphasizes cost control through process optimization and expenditure management [8] Shareholder Returns - The company approved a profit distribution plan in April 2025, which includes a cash dividend of 1.70 yuan per 10 shares and a capital reserve increase of 4.8 shares per 10 shares [9] - Future dividend policies will be based on operational performance and cash flow [21]

证券代码：001367 证券简称：海森药业 公告编号：2025-038 浙江海森药业股份有限公司 关于举行 2025 年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海森药业股份有限公司（以下简称"公司"）《2025年半年度报告》已 于2025年8月15日披露，为使投资者进一步了解公司的财务状况及经营情况，公 司将于2025年8月28日（星期四）15:30-16:30在全景网举行2025年半年度业绩说 明会，本次业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资 者关系互动平台"（https://ir.p5w.net）或者直接进入公司路演厅（https://ir.p5w. net/c/001367）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司副董事长王雨潇女士、董事兼总经理艾 林先生、独立董事戴文涛先生、财务总监潘爱娟女士、董事会秘书胡康康先生、 保荐代表人徐峰先生。 为充分尊重投资者、提升交流的针对性，现就公司2025年半年度网上业绩说 明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 ...

Group 1 - Zhejiang Haisen Pharmaceutical Co., Ltd. announced the promotion of Wu Yangkuan to Vice General Manager, effective August 2025 [1] - Wu Yangkuan, aged 32, has been with the company since 2018, holding various positions before his current promotion [1] - His current salary is reported at 126,400 RMB, significantly lower than the average salary for Vice General Managers, which exceeds 600,000 RMB [2] Group 2 - As of August 15, the company's total market value is approximately 4.08 billion RMB, with a stock price increase of 63.87% over the past year [3] - For the fiscal year 2024, the company achieved a revenue of 472 million RMB, representing a year-on-year growth of 18.63%, and a net profit of 123 million RMB, up 17.09% [3] - In the first half of 2025, the company reported revenues of about 242 million RMB, a 14.93% increase, and a net profit of approximately 60.79 million RMB, growing by 4.74% [3] - The company is expanding its production capacity and enhancing its research and development capabilities with new projects underway [3]

Group 1: Dongcheng Pharmaceutical - Dongcheng Pharmaceutical reported a 2.6% decline in revenue to 1.384 billion yuan for the first half of 2025, with net profit attributable to shareholders decreasing by 20.70% to 88.6525 million yuan [1] - The nuclear medicine segment generated sales of 503 million yuan, a year-on-year increase of 0.78%, with key product F-FDG achieving revenue of 212 million yuan, up 8.72% due to increased sales volume [1] - The raw material drug segment saw sales of 611 million yuan, down 7.02%, with heparin raw material revenue falling by 8.90% to 440 million yuan due to price declines, while chondroitin sulfate product revenue rose by 4.26% to 165 million yuan [1] Group 2: Haosen Pharmaceutical - Haosen Pharmaceutical experienced a 14.93% increase in revenue to 242 million yuan for the first half of 2025, with net profit rising by 4.74% to 60.7942 million yuan [2] - The raw material drug and intermediate business segments reported sales growth of 13.94% and 29.24% respectively, driving overall performance improvement [2] - The company achieved a significant 53.04% increase in overseas sales, supported by a strong focus on product quality and service, leading to an expanded market share [2] Group 3: Fuhong Hanlin - Fuhong Hanlin's application for the market registration of HLX04-O, a recombinant humanized monoclonal antibody injection for wet age-related macular degeneration, has been accepted by the National Medical Products Administration [3] - Currently, there are no approved products for this indication in China, highlighting a potential market opportunity [3] Group 4: Huazhong Medicine - Huazhong Medicine announced plans to invest up to 87 million yuan to establish a biopharmaceutical industry fund, targeting a total fundraising goal of 500 million yuan [5] - The fund aims to optimize the company's strategic layout in synthetic biology and enhance innovation incubation and product commercialization [6] Group 5: Xingqi Eye Medicine - Xingqi Eye Medicine has initiated the Phase II clinical trial for voriconazole eye drops, targeting fungal keratitis, a common cause of blindness in China [7] - Voriconazole is noted for its broad antimicrobial spectrum and low toxicity, with the trial designed to explore its efficacy and safety in patients [7] Group 6: East China Pharmaceutical - East China Pharmaceutical has signed an exclusive commercialization agreement for VC005 with Jiangsu Weikail, committing to an initial payment of 50 million yuan and potential milestone payments up to 180 million yuan [8] - The agreement grants East China exclusive rights for the oral formulation of VC005 in mainland China, indicating a strategic move to expand its product portfolio [8]

来源：上海证券报·中国证券网 上证报中国证券网讯 8月14日晚间，海森药业发布2025年半年度业绩公告。报告期内，公司实现营收2.42亿元，同比增长14.93%；归母净利润6079.42万元，同比增长4.74%。 海森药业主要产品为化学药品原料药、中间体，化学药品原料药及中间体，是医药制造业的重要组成部分，在整个医药制造产业链中处于上游位置。目前，公司已经形成以消化系统类、解热镇痛 公司表示，报告期内，公司主要产品市场订单充足，呈现供需两旺的良好态势。公司通过优化产能，保障供货稳定，同时，持续推进合格供应商备案工作，继续加强在美洲、欧洲等市场的开发力 此外，公司持续保持对于研发的较高投入，报告期内，研发费用为1771.09万元，占营收的7.32%，同比增长52.83%。截至报告期末，公司在研产品共计17项，包括原料药、中间体和制剂产品 ...

Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. reported a steady growth in its half-year performance, with revenue of approximately 242 million yuan, a year-on-year increase of 14.93%, and a net profit of about 60.79 million yuan, up 4.74% year-on-year, attributed to its international layout, R&D innovation, and market advantages of core products [1] Group 1: Financial Performance - The company's revenue from raw materials reached 207 million yuan, a year-on-year increase of 13.94%, while the intermediate business revenue was 28.76 million yuan, up 29.24% [2] - The overseas sales revenue grew by 53.04%, accounting for 55.61% of total revenue, reflecting the success of the company's international strategy [2] Group 2: R&D and Innovation - Haisen Pharmaceutical increased its R&D investment to 17.71 million yuan, a 52.83% increase year-on-year, representing 7.32% of its revenue, with 17 ongoing projects in various fields [3] - The establishment of the Hangzhou Haisen Drug Research Institute enhances R&D capabilities, and the new pilot workshop supports the transition from laboratory to industrial production [3] Group 3: Strategic Outlook - The company plans to continue its "raw materials + formulations" dual-driven strategy, focusing on core product markets and accelerating the industrialization of ongoing projects [4] - Haisen Pharmaceutical aims to leverage its technological accumulation, quality advantages, and international layout to strengthen its market position in the generic raw materials and specialty formulations sectors [4]

外资态度来看，本期较上一季度新披露的外资机构有 2 家 ，包括UBS AG、BARCLAYS BANK PLC。 2025年8月15日，海森药业(001367.SZ)发布2025年半年度报告。截至2025年8月14日，共有7个机构投资 者披露持有海森药业A股股份，合计持股量达6743.78万股，占海森药业总股本的44.39%。其中，机构 投资者包括浙江海森控股有限公司、东阳泰齐投资管理合伙企业(有限合伙)、UBS AG、BARCLAYS BANK PLC、J.P.Morgan Securities PLC-自有资金、高盛公司有限责任公司、MORGAN STANLEY & CO. INTERNATIONAL PLC.，机构投资者合计持股比例达44.39%。相较于上一季度，机构持股比例合 计上涨了0.67个百分点。 ...